Octapharma (Austria)

Recent papers from Octapharma (Austria)

1. Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative ApproachesPharmaceutical Research · 2026
2. High-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal before urgent surgery: subanalysis of the LEX-209 randomized, active-controlled trialResearch and Practice in Thrombosis and Haemostasis · 2026
3. Impact of secondary FVIII prophylaxis on joint bleeding and arthropathy in a Hemophilia A mouse model lacking inhibitor responseBlood · 2025
4. Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteinsResearch and Practice in Thrombosis and Haemostasis · 2025
5. Inhalative polyclonal immunoglobulin G for the prevention of respiratory infections: A comprehensive in vitro assessmentInternational Journal of Pharmaceutics X · 2025
6. Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM StudyRheumatology and Therapy · 2025
7. PredicDiff™: a computational tool for the prediction of PERLs concentrations based on extractables dataEuropean Journal of Pharmaceutical Sciences · 2025
8. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative reviewTransfusion and Apheresis Science · 2025
9. Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM studyLara D. Veeken · 2025
10. Comprehensive extractables and leachables sensitization analysis and practical application of a risk-based approach to sensitization assessment for parenteral drug productsRegulatory Toxicology and Pharmacology · 2025
11. Customizing subcutaneous immunoglobulin administration in primary antibody deficiency: patient-centric care perspectivesImmunotherapy · 2024
12. Validation of current commercially‐available devices to thaw pooled, solvent/detergent‐treated human plasmaTransfusion Medicine · 2024
13. Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex ConcentratesJAMA Network Open · 2024
14. Thirty years of experience with solvent/detergent‐treated plasma for transfusion medicineTransfusion · 2024
15. Evaluation of Autoantibody Status Effect on Dermatomyositis Patients’ Response to IVIG Treatment: Post-hoc Analysis of the ProDERM Trial (P4-14.007)Neurology · 2024
16. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM studyArthritis Research & Therapy · 2024
17. Simoctocog alfa (Nuwiq ® ) in children: early steps in life’s journey for people with severe hemophilia ATherapeutic Advances in Hematology · 2024
18. Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)Therapeutic Advances in Hematology · 2024
19. Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia AHaemophilia · 2023
20. Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping reviewClinical and Experimental Rheumatology · 2023